{"id":"W2961471425","doi":"10.1016/j.clml.2019.07.004","title":"Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia","year":2019,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"ca_institutions":"Juravinski Cancer Centre; McMaster University","funders":"Cilag; Janssen Pharmaceuticals; TG Therapeutics; H. Lundbeck A/S; BeiGene; Pharmacyclics; Genentech; Sunesis; Astellas Pharma; Exelixis; Sun Pharma; Regeneron Pharmaceuticals; F. Hoffmann-La Roche; AbbVie; Janssen Biotech; Teva Pharmaceutical Industries; Gilead Sciences; Janssen Research and Development; MorphoSys; Pfizer; Biogen; Celgene; AstraZeneca; Amgen; Alexion Pharmaceuticals; Roche; GlaxoSmithKline","keywords":"Ibrutinib; Medicine; Chronic lymphocytic leukemia; Oncology; Internal medicine; Leukemia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003791232,0.0002999213,0.0006961604,0.0005481787,0.0003893256,0.0007710584,0.0003689618,0.0005099166,0.0007537679],"category_scores_gemma":[0.004950022,0.0001473656,0.0008969107,0.001116599,0.0002802743,0.0005605991,0.000504688,0.0006392782,0.0001212471],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006069552,"about_ca_system_score_gemma":0.0004408353,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001024848,"about_ca_topic_score_gemma":0.002003796,"domain_scores_codex":[0.9987943,0.0004448399,0.0001816853,0.0002369871,0.0001793317,0.0001628543],"domain_scores_gemma":[0.9924448,0.002415425,0.003480886,0.0003180357,0.0006822875,0.0006585345],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.007935439,0.0001229082,0.9764208,0.000152919,0.002304093,0.00009344103,0.00008708741,0.0003036569,0.001106831,0.00001676792,0.0001883184,0.01126773],"study_design_scores_gemma":[0.0002236175,0.003092866,0.9930711,0.00006024842,0.00157087,0.0002619534,0.00008729246,0.0001876238,0.0004521087,0.00003514658,0.0009450593,0.00001217339],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9896498,0.009109971,0.0001627569,0.00008838481,0.00001494461,0.00001993309,0.0005674122,0.000003233429,0.0003835746],"genre_scores_gemma":[0.9976817,0.0008089822,0.00006789254,0.00007618526,0.00004483294,0.00003010705,0.001184144,0.000001852384,0.0001042868],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003791232,"threshold_uncertainty_score":0.02005017,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04643419086277679,"score_gpt":0.3793727557876246,"score_spread":0.3329385649248479,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}